Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial.
Shi Y, Fang J, Xing L, Yao Y, Zhang J, Liu L, Wang Y, Hu C, Xiong J, Liu Z, Yang R, Wang Z, Zhao E, Wang M, Zhao Y, Tang K, Li Z, Song Z, Li Y, Zhuang W, Jin B, Cheng Y, Hu Y, Gu Y, Wu L, Ma R, Yu Q, Yu Y, Zhao J, Zhao H, Lv D, Shang Y, Xing P, Zhou J, Li X, Liu Z, Dai Z, Xia G, Chen X, Ba Y, Bai C, Li Q, An G, Hu W, Wang Y, Wang-Gillam A, Ding Y, Li Q, Rao Z.
Shi Y, et al. Among authors: wu l.
Nat Med. 2025 Jan 6. doi: 10.1038/s41591-024-03401-z. Online ahead of print.
Nat Med. 2025.
PMID: 39762419